1.- Luzio JP, Mullock BM, Prior PR, Lindsay MR, James DE, Piper RC. Relationship between endosomes and lysosomes. Biochemical Society Transactions. 2001 29, (4): 476-480.

2.- Kart G. Concepts and Experiments En: Cell and Molecular Biology..2^a Ed. Nueva York, John Wiley & Sons, Inc. 1999. pag 304-323

3.- de La Sotta P, Romero W, González S. Utilidad de la biopsia renal en el diagnóstico de enfermedades neurológica 2008; Rev. Med. Chile 136 (8): 1047-1055.

4.- McGovern MM. Lysosomal Storage Disease En: Harrison Principles of Internal Medicine. 14^th ed. McGraw-Hill, USA; 1998: (2) pag:398-400.

5.- Lodish B, Berk A, Zipursky M, Matsudaira P, Baltimore D and Darnell J.Protein Sorting: Organelle Biogenesis and Protein Secretion. En: Molecular Cell Biology Baltimore and Darnell. 4^th Ed. W.H. Freeman New York 2000. Cap.17 pag 719

6. ?Eng CM, Banikazemi M, Gordon E, Golman M, Pkelps R, Kim L, Gass A, Winston J , et al. A Phase ½ Clinical Trial of Enzyme Replacement in Fabry Disease: Pharmacokinetic, Substrate Clearence, and Safety Studies. Am. J. Hum.Genet. 2001; 68:711-722

7.- Nobuhiro M, Eiichi A, Kohji M, Ryouhei Y, Noboru F, Kaku T, et. al. A Carboxy-terminal Truncation of Human α-Galactosidase A in a Heterozygous Female with Fabry Disease and Modification of the Enzymatic Activity by the Carboxy-terminal Domain. Am. Soc. Clin. Invest. 1996; 98 (8): 1809-1817.

8.- Pastores GM and Yeonh-Hau HL. Biochemical and Molecular Genetics Basis of Fabry Disease. J. Am. Soc. Nephrology. 2002; 13: S130-S133.

9- Lemansky M, Bishop DF, Desnick RJ, Hasilik A, von Figura K. Synthesis and Processing of α-Galactosidase A in Human Fibroblasts. J. Biol. Chem. 1987; 262 (5): 2062-2065.

10.- Garman SC and Garboczi DN. The Molecular Defect Leading to Fabry Disease: Structure of Human α- Galactosidase.J. Mol. Biol 2004; 337: 319-335.

11.- Torra R, Ballarín J. La Enfermedad de Fabry. Nefrología . 2003;13 (1):84-89

12.- Lyon MF. Gene Action in the X-chromosome of the Mouse (Mus musculus L.) Nature 1961,190, 372 - 373

13.- Gartler SM and Golman MA. X-Chromosome Inactivation. Encyclopedia of Live Sciences, 2001: 1-5.

14.- Ohshima T, Schiffmann R, Murria GJ, Kopp J, Quirk JM, Stahl S, et al. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc. Natl. Acad.Sci USA. 1999; 96:6423-6427.

15.- Morrone A, Cavicchi C, Bardelli T, Antuzzi D, Parini R, Di Rocco M, Feriozzi S, Gabrielli O, Barone R, et. al. Fabry Disease: Molecular studies in Italian patients and X inactivation analysis in manifesting carriers. J. Med Genet 2003;40: 1-6.

16 .- Schiffmann R, Murria GJ, Treco D, Daniel P, Sellos-Moura M, Myers JM, et. al. Infusión of α-galactosidase-A reduces tissue globotriaosylceramide storage in patients with Fabry disease.PNAS. 2000;97(4): 365 -370.

17.- Elleder M. Sequelae of storage in Fabry disease. Pathology and Comparison with other lysosomal storage disease. Acta Paediatr Suppl. 2003;92 (443):46-53.

18.- Sessa A, Moroni M, Batín G, Righetti M, Nebuloni M, Tosoni A, Vago GL. Evolution of renal pathology in Fabry Disease. Acta Paediatr Suppl.2003;92(443): 6-8

19.- Engel AG. The Scientific basis of Myology En: Engel AG and Banker BQ (eds). Myology Basic and Clinical. New York. McGraw-Hill 1986: 710-711.

20.- Carpenter S and Karpati G. Lysosomal storage in human skeletal muscle. Hum Pathol.1986; 17 (7):683-703.

21 .- Kai-Chung Tse, Kwok-Wah Chan, Pui-Chi Tin V, Pok-Siu Yip, Tang S, Fu-Keung Li, et al. Clinical features and genetic analysis of a Chinese kindrer with Fabry´s disease. Nephrol Dial Transplant (2003); 18:182-186

22.- Shoichiro Nakao, Chihaya Kodama, Toshihiro Takenaka, Akihiro Tanaka, Yuichiro Yasumoto. Fabry disease: Detection of undiagnosed hemodyalisis patients and identification of a ?renal variant? phenotype. Kidney International. 2003; 64: 801-807

23.- Robbins SL. Patología Estructural y Funcional. En Bases Patológicas de la enfermedad, 1^th eds. México D.F.: Editorial Interamericana 1975, 177-184

24 .-Kansaki T. Lysosomal storage disease with angiokeratoma corporis diffusum. Nippon Rinsho. 1995; 53(12):3062-3067

25.- Lao LM, Kumakiri M, Mima H, Kuwahara H, Ishida H, Ishiguro K, Fujita T, U. The ultrastructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidrosis. J. Dermatol Sci. 1998;18 (2) :109-117.

26.- Desnick RJ, Dean KJ, Grabowski G, Bishop DF and Sweeley CC. Enzyme therapy in Fabry disease: Differential in vivo plasma clearance and metabolic effectiviness of plasma and splenic α-galactosidase A isozymes. Proc. Natl. Acad.Sci. USA. 1979. 76 (10): 5326-5330.

27.- Sher NA, LetsonRD, Desnick RJ. The ocular manifestations in Fabry`s disease. Arch.Ophthalmol. 1979; 97(4):671-676.

28.- Warnock DG,. Renal aspects of Fabry Disease. Nephrology. 2003; 1(6):802-807.

29.-Germain DP. Fabry disease. Clinical and genetic aspects. Therapeutic perspectives. Rev.Med.Interne. 2000; 21(12):1086-1093.

30.- Mac Dermont J and Mac Dermont KD. Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J. Pharmacol. 2001;429(1-3) :121-125

31.- Brady RO, Tallman JF, Johnson WG, Gal AE, Leia WR, Quirk JM, Dekaban AS. Replacement Therapy for Inherited Enzyme Deficiency. New Engl J. of Med. 1973; 289 5(1): 9-14.

32.- Kornfeld S. and Mellman I. The biogenesis of lysosomes. Annu Rev Cell Biol 1989; 5: 483?525.

33.- Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, et al. Circulation 2004;110(9):1047-1053.

34.- Desnick R. Enzyme replacement therapy in Fabry disease: pathologic, biochemical, and immunologic results at 6 and 12 months of the Phase 3 extension study. Am J Human Genet 2001; 69:2895.

35.- .- Ioannou YA, Zeidner KM, Gordon RE, and Desnick R. Fabry Disease: Preclinical Studies Demonstrate the Effectiveness of α-Galactosidase A Replacement in Enzyme-deficient Mice. Am. J. Hum. Genet. 2001; 68: 14-25.

36.- Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, et al. A phase ½ Clinical trial of Enzyme Replacement in Fabry Disease: Pharcacokinetic, Substrate Clearence, and safety Studies. Am J. Hum. Genet 2001;68:711-722

37.- Alvarez L, del Pozzo C, Trigueros M, Sànchez L Alberto M, López-Menchero R y Ortega E. Terapia de sustitución enzimática en la Enferemdad de Fabry: evaluación clínico-histológica tras 18 meses de terapia. Nefrología 2005; 25(3): 322-327.